Aktienanalyse zu Arcus Biosciences Inc (RCUS)RCUSArcus Biosciences Inc

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcus Biosciences Inc (RCUS) is a good buy right now due to its current price of $24.41 being significantly lower than the analyst price targets, which range up to $43. The company has shown a strong year-over-year change of +46.69% and has a gross margin of 100%, indicating strong revenue generation potential. However, the main risk is the negative net income, which was -90 million USD in Q2 2026, reflecting ongoing financial challenges.

3 analysts cover RCUS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 27.44.